Switch from dolutegravir-based dual therapy to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in virologically suppressed adults with HIV-1

Phase 3, randomised, open-label trial of dolutegravir, elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide and 3 more in Human immunodeficiency virus infection type 1 (2 arms), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Proportion of subjects without residual viremia through 48 weeks of follow-up. Started Jun 2021; status: terminated.